APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn.Washington, DC: American Psychiatric Association.
Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews, CD005593. Review. PubMed PMID: 16437532
Bozoki, A. C., An, H., Bozoki, E. S. and Little, R. J. (2009). The existence of cognitive plateaus in Alzheimer's disease. Alzheimer's and Dementia, 5, 470–478.
Chandler, M. J.et al. (2005). A total score for the CERAD neuropsychological battery. Neurology, 65, 102–106.
Cortes, F.et al. (2005). Recent data on the natural history of Alzheimer's disease: results from the REAL.FR study. Journal of Nutrition, Health and Aging, 9, 86–93.
Cortes, F.et al. (2008). Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR study. Alzheimer's and Dementia, 4, 22–29.
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.
Cummings, J. L., Schneider, E., Tariot, P. N. and Graham, S. M. (2006). Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, 67, 57–63.
Feldman, H. H., Van Baelen, B., Kavanagh, S. M. and Torfs, K. E. (2005). Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Disease and Associated Disorders, 19, 29–36.
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.
Galasko, D.et al. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S33–39.
Hallikainen, I.et al. (2012). Cognitive and neuropsychiatric symptom differences in early stages of Alzheimer's disease: Kuopio ALSOVA study. Dementia and Geriatric Cognitive Disorders Extra, 2, 209–218. doi:10.1159/000338231.
Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. and Martin, R. L. (1982). A new clinical scale for the staging of dementia. The British Journal of Psychiatry, 140, 566–572.
Karttunen, K.et al. (2011). Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. International Journal of Geriatric Psychiatry, 26, 473–482. doi:10.1002/gps.2550. Epub 2010 Oct 29.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.
McLaughlin, T.et al. (2010). Assessment of potential measures in models of progression in Alzheimer disease. Neurology, 75, 1256–1262.
Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 2412–2414.
Morris, J. C.et al. (1989). The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 39, 1159–1165.
Morris, J. C.et al. (1993). The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology, 43, 2457–2465.
Pulliainen, V., Hokkanen, L., Salo, J. and Hänninen, T. (1999). CERAD-kognitiivinen tehtäväsarja. Käsikirja. [Manual of the Finnish version of the CERAD neuropsychological battery]. Kuopio: Suomen Alzheimertutkimusseura ry.
Rossetti, H. C., Munro Cullum, C., Hynan, L. S. and Lacritz, L. H. (2010). The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease. Alzheimer Disease and Associated Disorders, 24, 138–142.
Salloway, S.et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73, 2061–2070.
Seo, E. H.et al. (2010). Total scores of the CERAD neuropsychological assessment battery: validation for mild cognitive impairment and dementia patients with diverse etiologies. The American Journal of Geriatric Psychiatry, 18, 801–809.
Serra, L.et al. (2010). Relationship between cognitive impairment and behavioural disturbances in Alzheimer's disease patients. Behavioural Neurology, 23, 123–130.
Stein, J.et al. (2012). The assessment of changes in cognitive functioning: age-, education-, and gender-specific reliable change indices for older adults tested on the CERAD-NP battery: results of the German study on ageing, cognition, and dementia in primary care patients (AgeCoDe). The American Journal of Geriatric Psychiatry, 20, 84–97.
Steinberg, M.et al. (2008). Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 23, 170–177.
Stern, R. G.et al. (1994). A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. The American Journal of Psychiatry, 151, 390–396.
Tractenberg, R. E., Weiner, M. F., Cummings, J. L., Patterson, M. B. and Thal, L. J. (2005). Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. The Journal of Neuropsychiatry and Clinical Neurosciences, 17, 51–60.
Välimäki, T. H., Vehviläinen-Julkunen, K. M., Pietilä, A. M. and Pirttilä, T. A. (2009). Caregiver depression is associated with a low sense of coherence and health-related quality of life. Aging and Mental Health, 13, 799–807.
Welsh, K. A.et al. (1994). The consortium to establish a registry for Alzheimer's disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology, 44, 609–614.